食管癌手术患者临床特征及预后分析——2019年四川省肿瘤医院年度报告OA

Objective:Esophageal cancer(EC)remains a surgically oriented multimodal disease.Real-world data from high-volume EC treatment centers provide valuable guidance for clinical practice.This article describes the clinical character-istics,perioperative treatment status,and long-term survival outcomes of EC patients admitted to Sichuan Cancer Hospital in 2019.Methods:Clinical data were obtained from the prospective single-disease esophageal cancer database at Sichuan Cancer Hospital.We described the pathological characteristics,perioperative treatment modalities,and long-term survival outcomes of the patients included in this study.Results:A total of 325 EC patients were included,of whom 266(81.85%)were male.Most tumors were in the middle thoracic esophagus(56.00%)and were predominantly squamous cell carcinoma(92.92%).Neoadjuvant therapy was administered to 107 patients(32.92%)prior to surgery.The McKeown esophagecto-my was the most performed surgical procedure(91.08%).The 30-day postoperative mortality rate was 1.20%,and the R0 resection rate was 99.70%.The most common stage was pT3/ypT3.Postoperative complications were observed in 25.85%of patients.The 1-,3-,and 5-year overall survival(OS)rates were 85%,67%,and 63%,respectively.A 1:1 propensity score-matched analysis,accounting for baseline characteristics and pathological staging,showed that patients who received neoadjuvant therapy had significantly improved survival compared to those undergoing surgery alone(median OS:not reached vs 25 months;5-year OS rates:50.90%vs 29.70%;P=0.046).Conclusion:Patients undergoing esophagectomy via right thoracic approach with standardized lymph node dissection achieving R0 resection can achieve satisfactory long-term sur-vival outcomes.Patients with locally advanced resectable esophageal cancer treated with neoadjuvant therapy preoperatively can achieve improved long-term survival outcomes.